

Evelyne DELFOURNE et al.

IN THE ABSTRACT:

Please replace the abstract as originally filed which appears on the cover sheet of the Published application. Add new abstract as enclosed herewith on a separate sheet.

R E M A R K S

The above changes in the specification and claims merely place this national phase application in the same condition as it was during Chapter II of the international phase, with the multiple dependencies being removed. Following entry of this amendment by substitution of the pages, only claims 1-14 remain pending in this application. Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "VERSION WITH MARKINGS TO SHOW CHANGES MADE".

Respectfully submitted,

YOUNG & THOMPSON

By *Benoît Castel*
Benoît Castel
Attorney for Applicant
Customer No. 000466
Registration No. 35,041
745 South 23rd Street
Arlington, VA 22202
703/521-2297

February 12, 2002

"VERSION WITH MARKINGS TO SHOW CHANGES MADE"

Claim 6 has been amended as follows:

6. ~~((Amended))~~ The use of a compound as defined in ~~one~~
~~of claims 1 to 5~~ **claim 1**, for the manufacture of an anticancer
drug.

The abstract has been amended as follows:

ABSTRACT

The invention concerns a pharmaceutical composition comprising
an efficient amount of a compound selected among the compounds
of formulae (I) and ~~(Ia)~~ wherein: ~~R1, R2, R3, R4, R5, R6 and R7~~
~~are as defined in Claim 1. Said~~ ~~((Ia))~~. ~~The~~ compounds have
interesting cytotoxic properties leading to a therapeutic use
as antitumoral medicines.